Radionuclide Therapy: Chemistry and Applications
The aim of this meeting was to bring chemists and radiobiologists together with practitioners of radionuclide therapy including physicians, radiopharmacists and medical physicists to enhance interdisciplinary awareness and identify areas for chemical development that will widen the clinical use and improve efficacy of radionuclide therapy.
Chairs:
- Session 1: Dr Sue Clarke (Guy’s Hospital, London, UK)
- Session 2: Prof Phil Blower (Kings College London, UK)
- Session 3: Prof Alan Perkins (University of Nottingham, UK)
Local Organisers:
- Phil Blower, Jim Ballinger, Greg Mullen, Sheila Foolheea, Peter Liepins
Downloadable Files
Welcome and Introduction
Prof Phil Blower (Kings College London, UK)
PDF (49k)
Targeted Radionuclide Therapy – what are the issues?
Prof Steve Mather (Cancer Research UK, London, UK)
PDF (973k)
Bone Targeted Radionuclide Therapy
Dr Val Lewington (Royal Marsden Hospital, Sutton, UK)
PDF (394k)
New horizons in radionuclide therapy
Dr John Buscombe (Royal Free Hospital, London, UK)
PDF (603k)
Production of copper-64 and Cu-64 labelled bis(thiosemicarbazone) complexes
Dr Rowena Paul (PET Imaging Centre, St Thomas' Hospital, London, UK)
PDF (417k)
Selective toxicity of Cu-64-ATSM to hypoxic cells: potential for hypoxia-targeted radionuclide therapy
Dr Dan Lloyd (University of Kent, Canterbury, UK)
PDF (214k)
Alpha particle targeted radionuclide therapy
Prof Mike Zalutsky (Duke University, North Carolina, USA)
PDF (1109k)
Targeted radionuclide therapy: Practicalities and potentials
Prof Alan Perkins (University of Nottingham, UK)
PDF (1021k)
Development of new bifunctional chelators for copper and rhenium for radiopharmaceutical applications
Prof Jon Dilworth (University of Oxford, UK)
PDF (1303k)
Short talk: Anti-CD33 single chain antibody for radionuclide therapy of acute myeloid leukaemia
Dr Peter Nicholls (University of Kent, Canterbury, UK)
PDF (456k)
Targeting the bone marrow - radiolabelled antibodies in haematopoietic stem cell transplantation for leukaemia and myeloma
Dr Kim Orchard (Southampton General Hospital, UK)
PDF (1098k)
The bystander effect induced by intracellularly concentrated radionuclides
Prof Rob Mairs (Beatson Institute, Glasgow, UK)
PDF (1530k)
PDF files require 
Adobe Acrobat Reader
